Novartis NVS announced positive top-line results from the late-stage STEER study on experimental candidate intrathecal onasemnogene abeparvovec (OAV101IT). Intrathecal onasemnogene abeparvovec (OAV101IT) is an investigational, one-time gene therapy for patients with spinal muscular atrophy (SMA). The STEER study is a phase III randomized, double-blind, sham-controlled study evaluating the clinical efficacy, safety and tolerability of a one-time…